PTPRC

protein-coding

protein tyrosine phosphatase receptor type C, the group of Fibronectin type III domain containing|Protein tyrosine phosphatases receptor type|CD molecules

Gene summary

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitosis, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus is classified as a receptor type PTP. This PTP has been shown to be an essential regulator of T- and B-cell antigen receptor signaling. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signaling. This PTP also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signaling. Alternatively spliced transcripts variants of this gene, which encode distinct isoforms, have been reported. [provided by RefSeq, Jun 2012]

Previous symbols:
  • CD45

MANE transcript

NM_002838.5

Inheritance

AR

ClinVar variants

P:39U:405B:415

Top phenotype

Immunodeficiency 105, severe combined

gnomAD constraint

pLI —, LoF o/e 0.11

Max pathogenic AF

—

Genomic locus

chr1:198,638,457-198,759,342

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~120.9 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

immunodeficiency 104STRONG

Inheritance Pattern: AR

Disease ID:MONDO:0012163

Submitter: Labcorp Genetics (formerly Invitae)

T-B+ severe combined immunodeficiency due to CD45 deficiencySUPPORTIVE

Inheritance Pattern: AR

Disease ID:MONDO:0015702

Submitter: Orphanet

immunodeficiency 104MODERATE

Inheritance Pattern: AR

Disease ID:MONDO:0012163

Submitter: Ambry Genetics

immunodeficiency 104DEFINITIVE

Inheritance Pattern: AR

Disease ID:MONDO:0012163

Submitter: ClinGen

PTPRC was first reported in relation to severe combined immunodeficiency, T cell-negative, B cell-positive, NK cell-positive disease in 2000 (Kung C et al., 2000, PMID:10700239). PTPRC deficiency is an autosomal recessive disease that is usually diagnosed at the time of newborn screening (where applicable) and otherwise the first 6 months of life. If untreated, PTPRC deficiency SCID leads to death usually within the first year. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms (including Candida albicans, Pneumocystis carinii, and cytomegalovirus). It is characterized by failure to thrive (linked to the recurrent infections), normal or elevated numbers of natural killer cells (NK) and peripheral blood B cells, absent or very low peripheral blood T cells (severe T cell lymphopenia) and low or absent immunoglobulins. Patients also present with pancytopenia and decreased T-cell proliferation in response to mitogen. The curation of PTPRC related to autosomal recessive severe combined immunodeficiency with MONDO:0012163 ID (T cell-negative, B cell-positive, NK cell-positive) includes both case-level and experimental evidence. Five variants (one missense, one in-frame indel, one nonsense, one frameshift and one large deletion (that spans over part of PTPRC gene but has unknown size and boundaries)) reported in four probands in four publications (PMIDs: 10700239, 11145714, 22689986 and 26915675) are included in this curation. A score of 6.2 points for genetic evidence has been reached. The mechanism of pathogenicity appears to be loss of function (LOF). This gene-disease association is also supported by animal models, biochemical function and expression assays (PMIDs: 8334701, 8666928, 22724066, 2550143, 7428806, 8943569, 8428589, 1380033 and 28735895). Phenotypes of mice with PTPRC mutations were consistent with patients’ phenotypes, presenting normal or elevated numbers of B cells and low numbers or nearly absent mature T cells. Expression studies of CD45 in bone marrow and lymphoid tissues is consistent with the immunodeficiency associated with CD45 variation (PMID:7428806). Up-regulation of CD45 during positive selection is consistent with the stalling of T-cell maturation at the CD4+ CD8+ double-positive stage observed in patients with SCID due to CD45 variation (PMID: 8943569). CD45 is a phosphatase necessary for the activation of the kinase Lck (PMID: 8428589) that is critically needed to transduce signals downstream of T cell receptor triggering (PMID: 1380033). CD45 modulates Lck by dephosphorylating Tyrosine residues and it was observed that some of these residues and their phosphorylation status play an active part in the interaction between these two proteins (PMID: 28735895). CD45 has a large, heavily glycosylated extracellular domain, and this aspect plays important (and non-enzymatic) roles in activation of T cells and B cells by regulating the physical closeness of cell-surface molecules on antigen presenting cells with counter molecules on T cells. CD45 is alternately spliced upon activation of T cells, which regulates its physical size. A score of 6 points for experimental evidence has been reached, increasing the total score to 12.2 points. In summary, PTPRC is definitively associated with autosomal recessive severe combined immunodeficiency, T cell-negative, B cell-positive, NK cell-positive. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen SCID/CID GCEP on the meeting date December 16, 2021 (SOP Version 8).

immunodeficiency 105STRONG

Inheritance Pattern: AR

Disease ID:MONDO:0800104

Submitter: PanelApp Australia

Clinical Genomic Database (CGD)

Immunodeficiency 105, severe combinedAR

Manifestation: Allergy/Immunology/Infectious

Intervention: Allergy/Immunology/Infectious

Rationale: Antiinfectious prophylaxis and early and aggressive treatment of infections can be beneficial; BMT has been described

Refs: 9068311; 11145714; 22689986Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to PTPRC variants in ClinVar

10 Conditions Cataloged
Immunodeficiency 104Total: 1094
Inborn genetic diseasesTotal: 163
not providedTotal: 120
not specifiedTotal: 115
Immunodeficiency 105Total: 22
PTPRC-related disorderTotal: 22
Hepatitis C virus, susceptibility toTotal: 6
Severe combined immunodeficiency diseaseTotal: 2

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_002838.5. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
4
clinvar
381
clinvar
3
clinvar
388
missense
1
clinvar
384
clinvar
31
clinvar
416
nonsense
7
clinvar
1
clinvar
2
clinvar
10
start loss
1
clinvar
1
frameshift
10
clinvar
2
clinvar
12
splice donor/acceptor (+/-2bp)
1
clinvar
17
clinvar
14
clinvar
32
Total18214054123859

Highest pathogenic variant AF is 0.000012391635

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 47 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_002838.5RefSeqNP_002829.332MANE Select
ENST00000442510.8EnsemblENSP00000411355.332MANE Select
NM_001267798.2RefSeqNP_001254727.13Standard
NM_080921.4RefSeqNP_563578.229Standard

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Primary immunodeficiency - Homo sapiens (human)
  • Cell adhesion molecules (CAMs) - Homo sapiens (human)
  • T cell receptor signaling pathway - Homo sapiens (human)
  • Fc gamma R-mediated phagocytosis - Homo sapiens (human)
  • JAK-STAT-Ncore

Biological Process

  • activation of MAPK activity
  • natural killer cell differentiation
  • negative regulation of T cell mediated cytotoxicity
  • positive regulation of T cell mediated cytotoxicity
  • negative regulation of cytokine-mediated signaling pathway

Molecular Function

  • protein tyrosine phosphatase activity
  • transmembrane receptor protein tyrosine phosphatase activity
  • signaling receptor binding
  • protein binding
  • heparin binding

Cellular Component

  • plasma membrane
  • integral component of plasma membrane
  • focal adhesion
  • external side of plasma membrane
  • cytoplasmic side of plasma membrane

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000442510
Coding exons
32
Length
118745
Individuals with no LoFs
125705
Homozygous LoFs
1
Heterozygous LoFs
42
Defined
125748
p
0.000171
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense1.175976830.8740.00003418660
Missense (PolyPhen)171236.390.723393048
Synonymous-0.9022592411.070.00001262374
Loss of Function6.86869.90.1150.00000346881

Population LoF Frequency

PopulationCAFp-valueStatus
African0.000120.00012rare
Latino/Admixed American0.000170.00017rare
Ashkenazi Jewish0.0000990.000099rare
East Asian0.000490.00049rare
Finnish0.000140.00014rare
European (Non-Finnish)0.000110.00011rare
South Asian0.000330.00029rare
Other0.000160.00016rare

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity (By similarity). {ECO:0000250, ECO:0000269|PubMed:11909961, ECO:0000269|PubMed:2845400}.;
Disease
DISEASE: Severe combined immunodeficiency autosomal recessive T- cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]: A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. {ECO:0000269|PubMed:11145714}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Multiple sclerosis (MS) [MIM:126200]: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. {ECO:0000269|PubMed:11101853}. Note=Disease susceptibility may be associated with variations affecting the gene represented in this entry.;

Recessive Scores

pRec
0.670

Intolerance Scores

RVIS EVS
0.23
RVIS percentile EVS
68.57

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Essential (gene trap)
K
Indispensability pred.
E
Indispensability score
0.960

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.